This study explores how well certain drugs work for patients with meningiomas, which are tumors in the brain. The drugs being tested are vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib. These drugs aim to stop tumor growth by blocking specific enzymes (proteins that help cells grow). Patients are split into four groups based on the genetic changes in their tumors. Each group receives a specific drug. For example, patients with the SMO/PTCH1 mutation take vismodegib daily. The trial lasts in cycles of 28 days, and researchers check for side effects or signs of the tumor getting worse. Patients are followed up every 6 months for up to 5 years after treatment.

• Key Point 1: Participants are grouped by specific genetic mutations to receive targeted drugs.
• Key Point 2: Treatment cycles are 28 days long, with regular check-ups for up to 5 years.
• Key Point 3: The study requires no recent chemotherapy or surgery before starting.